Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Hla neutralizing antibodies (often misspelled as anti-HLA neutralization antibodies) are a class of monoclonal or polyclonal antibodies that target and neutralize the alpha-toxin (alpha-hemolysin, Hla) secreted by *Staphylococcus aureus*. Alpha-toxin is a key virulence factor that forms heptameric pores in host cell membranes (such as red blood cells, platelets, and endothelial cells) by binding to its cellular receptor, ADAM10, leading to cell lysis and tissue damage. By binding to Hla, these neutralizing antibodies prevent pore formation and protect host tissues from toxin-mediated injury. This therapeutic approach is being investigated for the prevention and treatment of *S. aureus* infections, including skin and soft tissue infections (SSTIs) and pneumonia, as an alternative or adjunct to traditional antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-Hla neutralizing antibody.